LRRK2
富含亮氨酸重复
激酶
帕金森病
疾病
遗传学
医学
药理学
生物信息学
生物
内科学
作者
Margaux Morez,Antonio Jesús Lara Ordóñez,Patricia Melnyk,Maxime Liberelle,Nicolas Lebègue,Jean‐Marc Taymans
标识
DOI:10.1080/13543776.2024.2378076
摘要
It can be expected that LRRK2 targeting strategies may proceed to phase III clinical testing for PD in the next five years, allowing the field to discover the real clinical value of LRRK2 targeting strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI